Lymphoma, B-Cell, Marginal Zone - 24 Studies Found
Recruiting |
: Marginal Zone Lymphoma Cohort in Korea : Lymphoma, B-Cell, Marginal Zone : 2016-04-04 : Other: Rituximab Cohort observation study |
Recruiting |
: Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma : Lymphoma, B-Cell, Marginal Zone : 2017-03-23 : Drug: Ibrutinib 560mg administered orally once daily. |
Completed |
: Endomicroscopy and Gastric MALT-lymphoma : MALT-lymphoma : 2012-01-08 :
|
Recruiting |
: Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) : Marginal Zone B-cell Lymphoma : 2015-04-05 : Drug: bendamustine plus rituximab Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 |
Active, not recruiting |
: Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma : MALT Lymphoma : 2013-03-06 :
|
Recruiting |
: Prospective Study of Frontline H Pylori Eradication in the Treatment of Early-stage Extragastric MALT Lymphoma : Mucosa-Associated Lymphoid Tissue Lymphoma : 2016-12-01 |
Not yet recruiting |
: A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) :
|
Completed |
: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma : Marginal Zone Lymphoma : 2007-03-27 :
|
Active, not recruiting |
: Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma : Non-gastric Marginal Zone Lymphoma : 2006-09-14 : Radiation: Involved Field Radiotherapy The prescribed dose |